PTGS2 and esophageal adenocarcinoma: Our group developed OAd controlled by cyclooxygenase-2 (Cox-2), Cox2-CRAd, for gastrointestinal cancers (e.g., pancreatic cancers [13], esophageal adenocarcinomas [43], and peritoneal dissemination of gastric cancer [44]).